Celgene Diversifies With $7.2B Receptos Buy
This article was originally published in The Pink Sheet Daily
Executive Summary
Celgene sees Receptos' ozanimod as a potential best-in-class drug for MS and inflammatory diseases like ulcerative colitis, largely because the S1P receptor modulator appears to have a lower CV and liver risk than other therapies in the class.